Displaying drugs 351 - 375 of 7376 in total
Corticotropin
Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis.
Approved
Investigational
Vet approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inducers ... Cytochrome P-450 CYP3A4 Inducers ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 Enzyme Inducers …
Lorpiprazole
Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2D6 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Memantine
Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's...
Approved
Investigational
Matched Categories: … Cytochrome P-450 CYP2A6 Inhibitors ... Cytochrome P-450 CYP2B6 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 CYP2A6 Inhibitors (weak) …
Cefditoren
Cefditoren is an oral third-generation cephalosporin. It is commonly marketed under the trade name Spectracef by Cornerstone BioPharma.
Approved
Investigational
Torasemide
Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993.
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP2C9 Substrates ... Cytochrome P-450 Enzyme Inhibitors …
Alprazolam
Alprazolam is a triazolobenzodiazepine indicated for the treatment of anxiety and panic disorders.[L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole.[L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms. Alprazolam's adverse...
Approved
Illicit
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2C9 Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A5 Substrates …
Capecitabine
Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C9 Inhibitors ... Cytochrome P-450 CYP2C9 Substrates ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C9 Inhibitors (strong) …
Ruxolitinib
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C9 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index …
1,2-Benzodiazepine
Benzodiazepine is under investigation for the prevention of Delirium and C.Surgical Procedure; Cardiac. Benzodiazepine has been investigated for the treatment of Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Flutamide
An antiandrogen with about the same potency as cyproterone in rodent and canine species.
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A5 Substrates …
Gilteritinib
Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other...
Approved
Investigational
Matched Categories: … Cytochrome P-450 Substrates ... P-glycoprotein substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A4 Substrates (strength unknown) …
Phenylephrine
Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939.
Approved
Matched Mixtures name: … T-P OFTENO ... T-P OFTENO ... G-P-tuss Dxp …
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers ... Cytochrome P-450 Enzyme Inducers ... Cytochrome P-450 CYP1A2 Inducers (strength unknown) …
Matched Categories: … Cytochrome P-450 CYP1A2 Inducers ... Cytochrome P-450 Enzyme Inducers ... Cytochrome P-450 CYP1A2 Inducers (strength unknown) …
Pramipexole
Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a non-ergot dopamine agonist drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement) . It was first approved by the FDA in 1997 . Parkinson's Disease is...
Approved
Investigational
Paspalum notatum pollen
Paspalum notatum pollen is the pollen of the Paspalum notatum plant. Paspalum notatum pollen is mainly used in allergenic testing.
Approved
Platanus hybrida pollen
Platanus hybrida pollen is the pollen of the Platanus hybrida plant. Platanus hybrida pollen is mainly used in allergenic testing.
Approved
Salmeterol
Salmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD.[L11545,L11548,L11551,L11554,L11557] It has a longer duration of action than the short-acting beta-2 adrenergic receptor agonist, salbutamol. Salmeterol was first described in the literature in 1988. Salmeterol's structure...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2C8 Inhibitors ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A5 Substrates …
Ziprasidone
Disorders such as schizophrenia and bipolar disorder can significantly impair mood, cognition, and behavior. These mental illnesses can often be accompanied by comorbidities such as depression and substance abuse, and can significantly impact the quality of life of patients and caregivers. Luckily, several treatment options for psychotic disorders have been...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A4 Inhibitors …
Trazodone
Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the...
Approved
Investigational
Matched Categories: … P-glycoprotein inducers ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2D6 Inhibitors ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP2D6 Substrates …
Daridorexant
Daridorexant, formerly known as nemorexant, is a selective dual orexin receptor antagonist used to treat insomnia. Insomnia is characterized by difficulties with sleep onset and/or sleep maintenance and impairment of daytime functioning. It chronically affects the person's daily functioning and long-term health effects, as insomnia is often associated with comorbidities...
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates …
Ergotamine
A vasoconstrictor found in ergot of Central Europe. It is an alpha-1 selective adrenergic agonist and is commonly used in the treatment of migraine disorders.
Approved
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Inhibitors ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Inhibitors …
Methsuximide
Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin.
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP2C19 Inhibitors ... Cytochrome P-450 Enzyme Inhibitors ... Cytochrome P-450 CYP2C19 Substrates ... Cytochrome P-450 CYP2C19 inhibitors (strength unknown) …
Vandetanib
Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.
On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Approved
Matched Categories: … Cytochrome P-450 Substrates ... P-glycoprotein inhibitors ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index …
Benzyl alcohol
Approved
Matched Categories: … Cytochrome P-450 Substrates ... Cytochrome P-450 CYP1A2 Substrates ... Cytochrome P-450 CYP2C8 Substrates ... Cytochrome P-450 CYP2D6 Substrates ... Cytochrome P-450 CYP2E1 Substrates …
Nisoldipine
Nisoldipine is a 1,4-dihydropyridine calcium channel blocker. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, nisoldipine prevents calcium-dependent smooth muscle contraction and subsequent vasoconstriction. Nisoldipine may be used in alone...
Approved
Matched Categories: … P-glycoprotein inhibitors ... Cytochrome P-450 Substrates ... Cytochrome P-450 CYP3A Substrates ... Cytochrome P-450 CYP3A4 Substrates ... Cytochrome P-450 CYP3A5 Substrates …
Displaying drugs 351 - 375 of 7376 in total